Introduction ! Herbal drugs are claimed to exert their unique mode of action by the complex interplay of many different constituents. Beyond actions of various constituents on more than a single target, it is postulated to also arise from mutual interactions of related chemical moieties at both the pharmacokinetic and pharmacodynamic level. It is therefore not surprising that herbal drugs may also have an effect on the activity of cytochrome P450 enzymes (CYPs), the most important enzyme family to mediate phase I metabolism of small molecule drugs and other human xenobiotics. This became particularly obvious when St. Johnʼs wort was recognized to be a potent inducer of CY-P3A [1] and other proteins involved in pharmacokinetics, and the detection of the inhibitory effects of grapefruit juice on gut wall CYP3A was a Abstract ! The extensive use of herbal drugs and their multiple components and modes of action suggests that they may also cause drug interactions by changing the activity of human cytochrome P450 enzymes. The purpose of the present review is to present the available data for the top 14 herbal drug sales in the U. S. Studies describing the effects of herbal drugs on phenotyping substrates for individual CYPs were identified by a comprehensive MEDLINE search. Drugs included Allium sativum (Liliaceae), Echinacea purpurea (Asteraceae), Serenoa repens (Arecaceae), Ginkgo biloba (Ginkgoaceae), Vaccinium macrocarpon (Ericaceae), Glycine max (Fabaceae), Panax ginseng (Araliaceae), Actea racemosa (Ranunculaceae), Hypericum perforatum (Hypericaceae), Silybum marianum (Asteraceae), Camellia sinensis (Theaceae), Valeriana officinalis (Valerianaceae), Piper methysticum (Piperaceae), and Hydrastis canadensis (Ranunculaceae) preparations. We identified 70 clinical studies in 69 publications. The majority of the herbal drugs appeared to have no clear effects on most of the CYPs examined. If there was an effect, there was mild inhibition in almost all cases, as seen with garlic or kava effects on CYP2E1 and with soybean components on CY-P1A2. The most pronounced effects were induction of CYP3A and other CYPs by St. Johnʼs wort and the inhibitory effect of goldenseal on CYP3A and CYP2D6, both being borderline between mild and moderate in magnitude. With the exceptions of St. Johnʼs wort and goldenseal, the information currently available suggests that concomitant intake of the herbal drugs addressed here is not a major risk for drugs that are metabolized by CYPs.
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St. Johnʼs wort t 1/2 : elimination half-life Phenotyping Studies to Assess the Effects of Phytopharmaceuticals on In Vivo Activity of Main Human Cytochrome P450 Enzymes reminder that natural products may be involved in drug interactions [2] . Nowadays, there is general agreement that the potential of herbal drugs to cause drug-drug interactions needs to be assessed as thoroughly as for non-herbal drugs, including interactions at the level of CYP-mediated metabolism. In vitro studies with herbal drugs probably are less reliable than those with individual chemicals because both effective concentrations in vitro as well as in vivo processing of the complex mixtures can hardly be predicted.
Because not all potential combinations with other drugs can be tested, the effect of drugs on individual enzymes is usually assessed using the phenotyping approach. Phenotyping for a CYP enzyme, i.e., quantification of its actual in vivo activity in an individual, is performed by administration of a selective substrate for this enzyme and subsequent determination of appropriate pharmacokinetic metrics closely reflecting enzyme activity [3] . Phenotyping substrates are usually marketed drugs with therapeutic indications, which are chosen mainly based on their selectivity for the CYP to be examined, on tolerability, and on availability.
The standard design of a respective clinical study is a crossover design with administration of the phenotyping agents in both periods, combined with coadministration of the drug to be tested at its highest chronic therapeutic dose in one period [3] . Current regulatory guidance has adopted this procedure and also provides recommendations on individual phenotyping agents [4, 5] . It is beyond the scope of this review to evaluate all individual substances and metrics used to quantify the effects of herbal drugs on individual CYPs in detail; for a respective assessment, see [3] . CYP phenotyping drugs recommended by the FDA [4, 5] include the following: CYP1A2, theophylline, caffeine; CYP2B6, efavirenz, bupropion; CYP2C8, amodiaquine, cerivastatin, repaglinide, rosiglitazone; CYP2C9, warfarin, tolbutamide; CYP2C19, omeprazole, esoprazole, lansoprazole, pantoprazole; CYP2D6, metoprolol, desipramine, dextromethorphan, atomoxetine; CYP2E1, chlorzoxazone; CYP3A4, midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, triazolam. The EMA list is more limited, comments on the lack of exhaustive validation of some agents, and also occasionally asks for monitoring of specific reactions. The FDA created and posted an additional extensive list in 2011 [6] presenting sensitive substrates (as mentioned in the 1999 document "Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies -Study Design, Data Analysis, and Recommendations for Dosing and Labeling", which formally is still valid today) and substrates with a narrow therapeutic range, but provides little advice on the selection of the individual agent. While caffeine, warfarin, tolbutamide, and midazolam, and most respective metrics derived from plasma concentrations may be considered as fully validated (with the limitations described above) [3] , caveats apply for the other listed substances, as additional metabolic pathways are known and/or validation data are limited. Several substances present in EMA and FDA lists had been withdrawn from the market prior to generation of the lists. A combination of substances in a phenotyping cocktail in order to address a panel of CYPs in a single clinical study has been studied extensively [3, 7, 8] . There should be no mutual interaction of the drugs within a cocktail; an excellent example how to study this in detail has been published [9] . The EMA guidance addresses cocktail studies, while for the FDA, only semiofficial information is available (see [10, 11] ), showing that the FDA also accepts data from cocktail studies. While in general the cocktail approach appears to be appropriate, the inclusion of "historical" substances with limited validation and/or affinity to several CYPs such as dapsone or quinidine may compromise the results for other cocktail components. Pharmacokinetic metrics, which reflect CYP activity best, may be metabolic ratios of a metabolite over a parent drug in plasma or urine, clearance of the parent drug, or partial clearance via a specific pathway, depending on the individual phenotyping substrate used. It is desirable to use metrics without the need of drawing many blood samples during the entire concentration vs. time profile of the phenotyping drug in order to keep burdens for both study participants and investigators as low as possible. Some metrics can indeed be derived using a limited sampling strategy (LSS) or even from a single sample [3] . However, the most recent 2010 EMA (draft) guidelines on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 -Corr.) as well as the respective FDA guidance website [12] ask explicitly for the determination of complete area under the curve (AUC) values of phenotyping substrates, requiring at least 8-10 samples per study period, and discourages the use of single concentrations and metabolic ratios. The reason for this reluctance to accept metrics derived using an LSS probably is that their validation is limited to the quantification of baseline activity in individuals without major diseases with effects on pharmacokinetics and in the absence of factors with a major impact on pharmacokinetics. However, any effects of interacting drugs may not be limited to the activity of the CYP to be investigated, but may also affect absorption, secondary metabolism, and other pharmacokinetic processes of the phenotyping substrate. Because of their multiple ingredients, herbal drugs would be at risk to unexpectedly exert such additional effects. LLS-based metrics presumably are less robust to such effects, with the risk that these would either be erroneously identified as an effect on CYP activity, or that existing effects on CYPs would be hidden. While the confounding mechanism could then be identified by a change in the entire concentration vs. time profile of the phenotyping drug, these may well go unnoticed with LLS-based metrics only. Furthermore, LLS and complete sampling may also reach different results in interaction studies [13] because the concentration of interacting moieties and, thus, the extent of interaction change during a dosing intervalwhich is only partially covered by an LLS. A second caveat concerns the estimation of the sample size required in interaction studies with herbal drugs. We repeatedly observed that the apparent intraindividual variability of phenotyping agent pharmacokinetics was clearly higher than reported in previous studies with small molecule drugs [14, 15] . The reason for this observation is unclear; one could speculate that nonspecific effects on gastrointestinal motility are involved. A higher safety margin when calculating the sample size appears to be the only way to handle this problem as long as the mechanisms are unclear.
The regulatory (i.e., safety) purpose of interaction studies with any drugs including herbal drugs is to investigate the maximal extent of interaction for maximal exposure towards the "perpetrator". To this end, effects on phenotyping metrics should be larger rather than smaller than the true effects on CYP activity (sensitive metrics). In contrast, true effects on CYP activity for a given dose would theoretically be required to adapt the dose of concomitantly given drugs subject to this interaction. For the latter approach, changes in enzyme activity could then be incorporated in simulations to predict the extent of interactions with other drugs [11] ; however, as these methods are at an early stage, the former approach currently still seems to be more appropriate.
In summary, the phenotyping approach is the method of choice to study the potential of drugs including herbal drugs to change CYP activity and thus the pharmacokinetics of their drug substrates, but much expertise and very close attention to the details of individual studies is required in order to understand the consequences of respective results. More research is needed especially to achieve better transferability of results to quantitatively predict effects of other drug substrates in treated patients.
Methods

!
The aim of the present review was to give a concise overview on herb-drug interactions in human clinical studies, especially phenotyping and phenotyping cocktail studies, with respect to the major human drug metabolizing cytochrome P450 enzymes. A literature search was conducted in MEDLINE (as accessed via PubMed on December 2, 2011) using the search terms of the plantʼs name in combination with "cytochrome P450′′, plus "drug interaction" or "herb-drug interaction". The search was limited to English and German language papers. For further information, reviews and additional publications from all reference lists were read and relevant data were extracted. The discussion of case reports, animal data as well as in vitro experiments were not the primary objective of the present review and were not included.
Results
!
We identified 70 clinical studies in 69 publications. An overview of the data is presented in l " 
Garlic [Allium sativum (L.) (Liliaceae)]
Garlic is the most popular herbal remedy. Postulated pharmacological actions of garlic include antibacterial, antiviral, antifungal, antihypertensive, blood glucose lowering, antithrombotic, antimutagenic, and antiplatelet actions [17] . Responsible for these activities are organosulfur compounds like alliin, allicin, diallyl disulfide, ajoene, and many others [18] . When the bulb is processed, alliin reacts with the enzyme allinase to produce the ac-tive constituent of garlic, allicin. Allicin is the compound often used to standardize many garlic formulations [19] . Garlic is available in different forms of pharmaceutical preparations, such as dry powder products, oil-macerated, volatile garlic oil, and juices of fresh garlic [20] . A clinical study assessed the effect of short-term administration of garlic supplements on single-dose ritonavir [21] , a protease inhibitor that is mainly metabolized by CYP3A4 [22] . Acute dosing of this garlic extract over 4 days did not significantly alter the pharmacokinetics of ritonavir. In another trial, 11 female patients with metastatic breast cancer were treated with the CYP3A4 substrate docetaxel and garlic for 12 consecutive days. Garlic supplementation had no statistically significant effects on the pharmacokinetic profile of docetaxel when administered over the short term (4 days) or long term (12 days) [23] . A further study investigated the effect of garlic (over 12 days) on CYP2C9 activity by using warfarin as the probe substrate and showed no effect on pharmacokinetics or pharmacodynamics of the probe [24] . Another clinical study with 14 normal volunteers found no influence of garlic on the activity of CYP3A4 and CYP2D6 by a consecutive intake of garlic for 14 days [25] . In contrast, other studies showed an effect of garlic preparations by long-term use longer than 14 days: A clinical study with 10 healthy volunteers demonstrated that long-term (21 days) use of garlic caplets led to a significant decline in the plasma concentrations of saquinavir [26] , an HIV-1 protease inhibitor that is metabolized by CYP3A4 [22] . The similarity in the magnitude of the decreases in AUC (− 51 %), C max (− 54%), and concentration at 8 hours (C 8 ) (− 49 %) suggested that garlic affected the bioavailability of saquinavir rather than its systemic clearance [26] . A cocktail interaction study in 12 healthy elderly subjects (mean = 67 years) who took garlic oil for 28 days showed no significant effects on CYP1A2, CYP2D6, and CYP3A4 activity, but it produced a significant decrease in CYP2E1 activity [27] .
In summary, garlic appears to have only a minor potential to cause herb-drug interactions, with CYP2E1 as the only identifiable target. The saquinavir case needs further investigation.
Echinacea [Echinacea purpurea (L.) Moench (Asteraceae)]
Echinacea has anti-inflammatory and immunomodulating properties and is widely used for the treatment of the upper respiratory tract [28] . Echinacea preparations are made from the roots and/or other parts of the plant by juicing, alcohol extraction, infusion, decoction, or consumed as tablets or capsules [29] . Echinacea preparations are not chemically standardized. The constituent base is complex, consisting of phenols (cichoric and caftaric acid), polysaccharides, and alkylamides. The immunomodulatory effect was reported to be caused by alkylamides, which bind to human cannabinoid receptors 1 and 2, and inhibit tumor necrosis factor α [30] . With a sales ranking of #2 in the U. S. market [16] , it is very important to determine the ability of echinacea to effect metabolic drug-drug interactions. Clinical studies indicate conflicting data about the effect of echinacea on the hepatic drug oxidation system. In a cocktail interaction study with 12 healthy volunteers, CYP1A2 was inhibited as assessed by a reduced oral clearance of the CYP1A2 probe caffeine (− 27%, p = 0.049), there was a minor inhibitory effect on CYP2C9 (− 11 %, p = 0.001), while there was no effect on CYP2D6 or CYP3A4 [31] . Two further clinical studies determined the influence of echinacea on CYP3A4. In one of these studies, 13 healthy volunteers were dosed with lopinavirritonavir and the probe substrate midazolam. Neither lopinavir nor ritonavir pharmacokinetic parameter values were significantly altered after 14 days of echinacea administration [32] . The other study in 12 healthy male volunteers conducted with warfarin, a substrate of CYP2C9 and CYP3A4 for S-warfarin, and CYP3A4 and CYP1A2 for R-warfarin [33] , found no clinically significant pharmacokinetic and pharmacodynamic interaction [34] . In a cocktail interaction study with 12 healthy volunteers determined by Gurley et al. [35] , long-term supplementation of echinacea had no effect on CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity [35] . The same research group assessed the influence of echinacea on the activity of CYP2D6 in a clinical study with 18 normal volunteers, again with no effects [36] . In summary, the results of all described studies propose that echinacea has a fairly low capability for causing herb-drug interactions with human cytochrome P450 enzymes.
Saw palmetto [Serenoa repens (W. Bartram) Small (Arecaceae)]
Saw palmetto is the most popular herbal remedy used to alleviate the symptoms related to benign prostatic hyperplasia [37] . It has an ability to improve urologic symptoms and urine flow measures comparable to that of finasteride [35] . Saw palmetto extracts gained from the ripe, dried fruit have anti-inflammatory and spasmolytic properties. Most saw palmetto extracts are composed of mixtures of fatty acids including capric, caprylic, lauric, linoleic, linolenic, myristic, oleic, palmitic, and stearic acids, which typically account for 80-90 % of the extract [38] . There are only two clinical studies that have assessed the impact of saw palmetto on human cytochrome P450 enzymes. A cocktail interaction study with 12 healthy volunteers demonstrated that saw palmetto had no significant modulatory effects on CYP1A2, CYP2D6, CYP2E1, and CYP3A4 [35] . Another clinical study with 12 normal volunteers determined whether saw palmetto affects the activity of CYP2D6 and CYP3A4. For the probe substrates dextromethorphan (CYP2D6 activity) and alprazolam (CYP3A4 activity), the results indicated a lack of effect [38] .
Overall, saw palmetto extract at generally recommended doses seems to be an unlikely candidate for CYP-mediated herb-drug interactions.
Ginkgo [Ginkgo biloba (L.) (Ginkgoaceae)]
Ginkgo extract is a popular herbal remedy used for a variety of disorders. EGb 761 ® special extract, for example, is a dry extract from Ginkgo biloba leaves (drug-extract ratio 35-67 : 1) that has been adjusted to 22-27 % ginkgo flavonoids and 5.0-7.0 % terpene lactones consisting of 2.8-3.4 % ginkgolides A, B, C and 2.6-3.2 % bilobalides, with a ginkgolic acid content less than 5 ppm [39] . EGb 761 ® interferes with various pathomechanisms relevant to dementing disorders [40] [41] [42] . A large number of clinical studies suggest that Ginkgo biloba extract (GBE) may have beneficial effects on memory, cognition, and the vascular system [43] [44] [45] [46] [47] .
For an herbal drug to be taken by elderly people, often with several chronic diseases, the ability of GBE to cause metabolic drugdrug interactions should be known. The literature exhibits conflicting data, particularly on long-term treatment of 12 days and more. A clinical study in 11 healthy volunteers assessed the effect of GBE on the activity of CYP2C9 using flurbiprofen as a substrate. The subjects took 2 × 60 mg EGb 761 ® tablets thrice daily for 1 day. There was no significant difference between ginkgo or placebo treatment in any of flurbiprofenʼs kinetic parameters [48] . Another research group also could not find any effect of ginkgo, neither inducing nor inhibiting, on CYP1A2, CYP3A4 and CYP2C9 activity using racemic warfarin as a probe drug in 12 healthy male subjects, who took ginkgo for 7 consecutive days [49] . Using a cocktail phenotyping approach, a study with 18 healthy volunteers provided evidence that EGb 761 ® had no clinically relevant inhibitory or inducing effects towards human CY-P1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 when administered at chronic therapeutic doses for 8 days [15] . A clinical study with 18 healthy Chinese subjects investigated the potential herbdrug interaction between ginkgo and omeprazole, a widely used CYP2C19 substrate [50] . The volunteers had taken ginkgo tablets 2 × 70 mg twice daily for 12 days. In this study, plasma concentrations of omeprazole were significantly decreased and 5-hydroxyomeprazole as its metabolite significantly increased following ginkgo administration in comparison to baseline indicating an induction of CYP2C19 [50] . In contrast, a clinical study performed in 14 Chinese volunteers examined the possible effects of ginkgo as an inducer of CYP2C19 on single-dose pharmacokinetics of voriconazole [51] . Ginkgo pretreatment for 12 days did not significantly affect pharmacokinetic parameters of voriconazole [51] . A clinical study evaluated as the primary objective the effect of GBE on the exposure of lopinavir, an HIV protease inhibitor metabolized by CYP3A4, in 14 healthy volunteers [52] . The secondary objectives were to compare ritonavir exposure pre-and post-GBE, and assess the effect of GBE on single doses of the probe drug midazolam. Ginkgo biloba extract decreased midazolam AUC (0-∞) by 34% (p = 0.03) and C max by 31% (p = 0.03) but did not significantly affect the exposures of lopinavir and ritonavir [52] . A clinical study performed in 14 healthy male volunteers determined the effects of GBE on the pharmacokinetics of bupropion, a substrate of CYP2B6. Ginkgo biloba extract administration of 240 mg · day −1 (two 60-mg capsules taken twice daily) for 14 days did not significantly alter the basic pharmacokinetic parameters of bupropion [53] . Another clinical study with 12 healthy volunteers assessed the influence of GBE on the activity of CYP2D6 and CYP3A4 for about 14 days. For the probe substrates dextromethorphan (CYP2D6 activity) and alprazolam (CYP3A4 activity), no statistical differences were observed between baseline and post-GBE treatment indicating a lack of effect on CYP2D6 and CYP3A4 [54] . In a cocktail interaction study with 12 healthy volunteers and treatment duration of 28 days, no significant effect on CYP1A2, CYP2D6, CYP2E1, and CYP3A4 activity for Ginkgo biloba was found [27] . But other studies observed that ginkgo inhibits CYP3A4 [55, 56] . A study with 15 subjects showed that the geometric mean midazolam AUC (0-∞) prior to GBE administration was reduced by 34 % after GBE administration [55] . The outcome of the study of Uchida and colleagues performed in 10 male healthy volunteers was an inhibiting effect of GBE on CYP3A4 activity as shown by an increased AUC (0-∞) by 25% and decreased oral clearance by 26 % of midazolam, and an inducing effect on CYP2C9 activity according to a reduced AUC (0-∞) by 16 % of tolbutamide [56] . A pharmacokinetic study in healthy volunteers conducted with diazepam as a substrate of CYP2C19 did not suggest the presence of an herb-drug interaction [57] .
Altogether, it appears that GBE may have some effect on the activity of CYP enzymes when applied in patients, probably depending on the preparation used.
Cranberry [Vaccinium macrocarpon (Aiton) (Ericaceae)]
Cranberries are primarily cultivated for consumption as foods and beverages [58] . Products of the cranberry industry include fresh fruit (5%), juices (60%), sauces, dried fruit, and ingredients (35%), such as frozen fruit, juice concentrates, and spray-dried powders [59, 60] . Cranberry juice contains phytochemicals such as proanthocyanidins, flavonols, and quercetin [61] . The juice and concentrated extracts of cranberries are increasingly popular among consumers because of its use for the prevention and adjunctive treatment of urinary tract infections [58] . Moreover, cranberry juice shows efficacy in reducing urinary tract infections by acidifying the urine [62] and in reducing bacteriuria in elderly persons [63] . It also features positive effects against drug-resistant bacteria [64] . The large popularity of cranberry juice should give reason to examine its ability to cause herb-drug interactions. There are only a few data available. A clinical study in 8 healthy volunteers investigated the potential interaction between cranberry juice and diclofenac, a substrate of CYP2C9. An intake of 180 mL of cranberry juice twice a day for 5 days did not change the pharmacokinetics of diclofenac [65] . Another clinical study evaluated the effect of cranberry juice and other beverages on CYP2C9 activity. Fourteen healthy volunteers received flurbiprofen as a probe substrate for CYP2C9 in combination with 8 oz. of cranberry juice. None of the beverages altered CYP2C9-mediated clearance of flurbiprofen in humans [66] . Further investigations on CYP2C9 in clinical studies showed that cranberry juice also had no interaction potential on the pharmacokinetics of warfarin [67, 68] . In addition to CYP2C9, Lilja and colleagues assessed the effect of cranberry juice on the activities of CYP1A2 and CYP3A4. Ten healthy volunteers took 200 mL cranberry juice thrice daily for 10 days. They observed no effects of cranberry juice on the pharmacokinetics of tizanidine (as CYP1A2 probe) and midazolam (as the CYP3A4 probe) [68] . Another clinical study in 12 healthy male volunteers revealed that an intake of 240 mL of cranberry juice did not affect the pharmacokinetics of cyclosporine as a substrate of CYP3A [69] . In summary, daily ingestion of more than 1 glass of cranberry juice seems not to alter the activities of cytochrome P450 enzymes.
Soy [Glycine max (L.) Merr. (Fabaceae)]
Soy is a plant native to East Asia, commonly grown for its bean, which has been reported to have various health benefits. Soybeans provide ample amounts of α-linolenic acid [70] and significant amounts of isoflavones. Three soybean isoflavones, genistein, daidzein, and glycitein, and their various glycoside forms account for roughly 50, 40, and 10 %, respectively, of total isoflavone content [71] . Epidemiological and experimental researchers have provided extensive information on the anti-estrogenic effects of soy isoflavones on human health [72] . In China, Japan, Korea, and other countries in the Far East as well as lately in Western countries, the bean and products made from it such as soy sauce, soy flour, soy milk, and tofu are a popular part of the diet. Hence, it is very important to take the ability of soy for an herbdrug interaction into account. A clinical study performed in 20 healthy volunteers examined the potential effect of daidzein on CYP1A2 activity and on the pharmacokinetics of theophylline as a probe substrate [73] . Plasma concentrations and derived parameters including AUC (0-48) , C max , and t 1/2 were significantly increased by approximately one-third [73] . Another clinical study investigated the effect of 1 g genistein once daily for 14 days on the caffeine-based metrics of CYP1A2 and CYP2A6 in 18 healthy female volunteers [74] . Genistein decreased the urinary caffeine metabolite ratio used to assess CYP1A2 activity by 41 %, whereas the urinary ratio for CYP2A6 activity increased by 47 %, suggesting that genistein inhibited CYP1A2 and induced CYP2A6 [74] . A clinical study in 18 healthy Chinese female volunteers provided no effects of soy extract on the pharmacokinetics of losartan as a substrate of CYP2C9 and CYP3A4 [75] . A clinical study assessed the drug interaction potential of soy extract on CYP3A using the urinary excretion of the 6β-hydroxycortisol/cortisol ratio as a marker of enzyme induction. Twenty healthy subjects received a soy extract containing 50 mg isoflavones twice daily for 14 days. The soy extract had no effect [76] . Altogether, soybean constituents may be weak inhibitors of CY-P1A2, which translates into clinical relevance only in extraordinary situations.
Asian ginseng [Panax ginseng (L.) (Araliaceae)]
Asian ginseng (ginseng) is marketed for a wide range of indications, which include erectile dysfunction, cancer prevention, enhanced physical function, and improved cognitive functions [77] . Ginseng extracts are generally standardized to ginsenosides. Ginsenosides are a class of steroid glycosides and triterpene saponins [78] . The roots of Panax ginseng contain at least 25 different triterpene saponins [79] . Ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, and Rg1 are reported as major constituents and each ginsenoside has been shown to have different pharmacological effects, including immune system modulation, antistress activities, and antihyperglycemic activities, anti-inflammatory, antioxidant, and anticancer effects, antiplatelet, antithrombotic, vasodilatory, cardiotonic, angiogenic, and neuroprotective effects [79] [80] [81] [82] .
For an herbal drug to be widely used by the elderly community for a variety of indications, the ability of ginseng to cause metabolic drug-drug interactions should be determined. Clinical studies in humans have shown that Panax ginseng has no effect on a number of CYP enzymes [77] . In a cocktail interaction study with 12 healthy elderly volunteers (mean = 67 years), Panax ginseng inhibited CYP2D6 activity assessed using debrisoquine urinary recovery ratios significantly, but only by 7.0% [27] . No significant effect on CYP1A2, CYP3A4, or CYP2E1 activity for Panax ginseng was found [27] . One trial investigated the interaction between warfarin and Panax ginseng in ischemic stroke patients. Twentyfive patients were enrolled in the study; twelve patients in the ginseng group received Panax ginseng and warfarin for 2 weeks, and the control group (n = 13) received only warfarin for the same duration of time. There were no statistically significant differences between the ginseng group and control group [80] . Another study in 12 healthy male subjects conducted to investigate the effect of ginseng on the pharmacokinetics and pharmacodynamics of warfarin found no clinically significant changes in AUC, t 1/2 , and apparent total clearance [83] . This study confirmed that ginseng had no effect on the activity of CYP1A2, CYP3A4, or CYP2C9 in healthy volunteers [83] . Another clinical study could also not show any effect of Panax ginseng on CYP3A. Twenty healthy subjects received 100 mg Panax ginseng standardized to 4 % ginsenosides twice daily for 14 days. The urinary excretion of the 6β-hydroxycortisol/cortisol ratio was used as a marker of CY-P3A induction but no significant alteration was observed for Panax ginseng [76] .
In summary, it appears that Asian ginseng has no effect on the activity of CYP enzymes in vivo.
Black cohosh [Actaea racemosa (L.) Nutt.
(Ranunculaceae)]
Extracts of black cohosh are made from the roots and rhizomes of the plant. Black cohosh preparations (tinctures or tablets of dried materials) are commonly used as an alternative to hormone ther-apy in perimenopausal women to treat symptoms such as hot flashes, vaginal dryness, and mood swings [19, 84] . A few clinical studies conducted the effect of black cohosh on human cytochrome P450 enzymes. A cocktail interaction study with 12 healthy volunteers showed no significant effects of black cohosh on CYP1A2, CYP2E1, and CYP3A4 activity, but it did have an effect on CYP2D6 [85] . Black cohosh exhibited a statistically significant decrease in the CYP2D6 phenotype (p = 0.02), but the magnitude of the result (~7.0 % reduction) is not clinically relevant [85] . In another clinical study with 18 normal volunteers, Gurley et al. assessed the influence of black cohosh only on the activity of CYP2D6 to corroborate their earlier findings. This time, comparisons of pre-and post-supplementation of 8-hour debrisoquine urinary recovery ratios revealed no statistically significant effects on CYP2D6 [36] . Another pharmacokinetic study in 19 healthy volunteers conducted with midazolam as a substrate of CYP3A also did not suggest the presence of an herb-drug interaction [86] .
In summary, black cohosh appears to have no clinically relevant effects on cytochrome P450 activity.
St. Johnʼs wort [Hypericum perforatum (L.) (Hypericaceae)]
St. Johnʼs wort (SJW) is an herbaceous perennial plant native to Europe. Extracts obtained from the aerial parts of Hypericum perforatum have been recommended traditionally for a wide range of medical conditions [87] . St. Johnʼs wort is commonly used to treat mild-to-moderate depression but is also used to treat anxiety, obsessive-compulsive disorder, and premenstrual syndrome [19] . The extracts of SJW contain numerous pharmacologically active ingredients, including naphthodianthrones (e.g., hypericin and its derivatives) and phloroglucinols derivatives (e.g., hyperforin, which inhibits the reuptake of a number of neurotransmitters, including serotonin) [87] . The most common recommended dose is 900 mg per day standardized to 0.3 % hypericin to treat depression [19] . Several clinical studies have clearly revealed that SJW may alter CYP activity. Many of the interaction studies indicate that SJW is a potent inducer of CYP3A4, CYP2E1, and CYP2C19, with no effect on CYP1A2, CYP2D6, or CYP2C9 [20, 77] . The effect of SJW on CY-P3A4 is seen after long-term treatment. Markowitz et al. assessed the effects of SJW on CYP2D6 and CYP3A4 activity. Seven normal subjects received 3 times daily a commercial SJW formulation (Solaray ® ) 300 mg, standardized to 0.3 % hypericin for 4 days. Dextromethorphan (CYP2D6 activity) and alprazolam (CYP3A4 activity) were administered as probe substrates. No statistically significant differences were found in any estimated pharmacokinetic parameter for alprazolam or dextromethorphan for this short-term treatment [88] . A cocktail interaction study with 12 healthy volunteers examined the effect of SJW on CYP activity. Tolbutamide (CYP2C9), caffeine (CYP1A2), dextromethorphan (CYP2D6), oral midazolam (intestinal wall and hepatic CYP3A), and intravenous midazolam (hepatic CYP3A) were administered before, with short-term SJW dosing (900 mg), and after 2 weeks of intake (300 mg 3 times a day) to determine CYP activities [89] . Short-term administration of SJW had no effect on CYP activities. Long-term SJW administration caused a significant (p < 0.05) increase in oral clearance of midazolam and a corresponding significant decline in oral bioavailability [89] . There are many other clinical studies that confirm these findings. Another clinical cocktail interaction study assessed the influence of SJW on the activity of CYP1A2, CYP2D6, and CYP3A4. Eight healthy male and 8 healthy female subjects were treated with SJW extract (3 × 300 mg · day −1 ) for 14 days [90] . After 2 weeks of treatment with SJW, the mean increase in the 6β-hydroxycortisol/cortisol molar concentration ratio in urine, used as an index of activity of CYP3A4, was 85 %. Additionally, the authors found a slight (but not significant) increase in the paraxanthine/caffeine ratio in saliva after SJW. However, most of the subjects exhibiting an apparent induction of CYP1A2 were females [90] . No influence of SJW on CYP2D6 activity was found [90] . A clinical cocktail interaction study performed in 12 elderly subjects (mean = 67 years) assessed the pre-and post-supplementation phenotypic ratios for CYP3A4, CYP1A2, CYP2E1, and CYP2D6 [27] . Twentyeight days of SJW supplementation resulted in a 141 % increase in the mean one-hour 1-hydroxymidazolam/midazolam serum ratio (p < 0.001) [27] . Similar to its effect on CYP3A4, SJW produced significant increases in CYP2E1 activity (p = 0.006). No statistically significant differences in mean values were noted for CYP1A2 and CYP2D6 [27] . In a later clinical study performed by the same researchers [36] , no significant differences were observed among the mean baseline debrisoquine urinary recovery ratio by supplementation of 14 days of SJW. In contrast to Wenk and colleagues, no sex-related changes in CYP phenotypes were noted. Two further clinical studies suggested that SJW is an inducer of CYP3A4 following 14 days of treatment [91, 92] . There are also two clinical studies which determined the effect of SJW on CYP2C19 activity. In each study, 12 healthy volunteers received a 300-mg SJW tablet 3 times daily for 14 days. In one study, the activities of CYP2C19 and CYP1A2 were measured using mephenytoin and caffeine, respectively [93] , and in the other study, the activities of CYP2C19 and CYP3A4 were measured using omeprazole [94] . In both studies, it was found that SJW treatment significantly increased CYP2C19 activity. Furthermore, clinical data imply that hyperforin content affects the extent of SJW interactions, since extracts with a low hyperforin amount had a weak or no effect on CYP activity. A clinical study compared the effects of 2 SJW preparations with high and low hyperforin content on the pharmacokinetics of cyclosporine. In a crossover study, 10 renal transplant patients were randomized into 2 groups and received SJW extract 300 mg (two 150 mg capsules) 3 times a day (total dose, 900 mg/d) containing low or high concentrations of hyperforin for 14 days in addition to their regular regimen of cyclosporine [95] . The study showed a significant difference between the effects of the 2 SJW preparations on cyclosporine pharmacokinetics. The area under the plasma concentration-time curve, within one dosing interval (AUC 0-12 ; p < 0.0001), values with high hyperforin SJW comedication were 45 % lower (95 % CI − 37% to − 54%; p < 0.05) than for low hyperforin SJW [95] . Arold and colleagues performed two clinical interaction studies with 28 healthy volunteers in each study. In study A, alprazolam (CYP3A4) and caffeine (CYP1A2), and in study B, tolbutamide (CYP2C9) and digoxin (p-glycoprotein), were given as probe substrates, respectively. The participants received SJW with a low hyperforin content (Esbericum ® capsules; 240 mg · day −1 , 3.5 mg hyperforin) or placebo for 10 days. No statistically significant differences were found in the primary kinetic parameters between the placebo group and the SJW group at the end of both studies [96] . Another two clinical studies conducted by Mueller and colleagues evaluated the effect on CYP3A function of SJW preparations with a wide range from very low to high hyperforin content. In the first study, 42 healthy volunteers were randomized into 6 different SJW medication groups for 14 days.
A single oral dose of midazolam was used as a probe substrate.
All SJW preparations tested resulted in a decrease in midazolam AUC, although the extent of the effect differed [97] . [98] . No significant changes were observed after SJW treatment regarding midazolam C max , t max , and t 1/2 (p > 0.05) [98] . Apart from using probe drugs in clinical interaction studies to show that SJW is a potential inducer of CYP3A4, CYP2E1, and CYP2C19, SJW has also been shown to have the ability to clinically interact with a number of frequently used drugs. St. Johnʼs wort may reduce the efficacy of oral contraceptives (e.g., induction of ethinyl estradiol-norethindrone metabolism [99, 100] ; decrease in serum 3-ketodesogestrel concentrations [101] ), may reduce the pharmacokinetics of imatinib by increasing its clearance [102, 103] , may interact with cardiovascular drugs (e.g., decreased plasma concentrations of atorvastatin [104] , ivabradine [105] , and R-and S-verapamil [106] ), may induce the apparent clearance of both S-and R-warfarin, which in turn resulted in a significant reduction in the pharmacological effect of rac-warfarin [83] , may interact with drugs acting on the central nervous system (e.g., decreased plasma concentration of quazepam [107] , alprazolam [92] , and midazolam [27, 89, 97, 99] ), may reduce plasma voriconazole concentrations after long-term but not short-term administration [108] , may alter gliclazide pharmacokinetics [109] , and may reduce the AUC of the HIV-1 protease inhibitor indinavir [110] . In summary, clinical evidence of the effects of SJW on CYP enzymes is undisputed. There are numerous studies which have shown that the inducing effect of SJW depends on treatment duration and the preparation, primarily the amount of hyperforin.
Patients and physicians should be well informed about the interaction potential of St. Johnʼs wort.
Milk thistle [Silybum marianum (L.) Gaertn. (Asteraceae)]
Extracts of milk thistle are recognized for the treatment of liver injury. The active principle is a mixture of flavolignans called Silymarin [20] . Silymarin is made from the seeds of milk thistle and is composed of six closely related flavonolignans (silibinin, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin) and one flavonoid (taxifolin) [111] . Silibinin, the major active constituent of silymarin, consists of 2 diasteroisomers, silybin A and silybin B [111, 112] . Silymarin has cytoprotective, antioxidative, and radical scavenging as well as anti-inflammatory and antifibrotic properties [14] . It is used to self-treat hepatic disorders, including hepatitis C and cirrhosis, and as a hepatoprotectant, particularly for mushroom poisoning [113] . For a popular herbal product to be taken for hepatoprotection and chemoprevention, the ability of milk thistle extract to cause metabolic drug-drug interactions should be known. Several in vivo studies in humans indicate that milk thistle has no effect on the hepatic drug oxidation system. A clinical study was con-ducted to examine the effect of silymarin on cytochrome P450 3A4. Sixteen healthy male volunteers were administered with immediate release nifedipine as a CYP3A4 test drug either alone or with the coadministration of silymarin. The coadministration of silymarin for 1 day did not considerably change the extent of absorption or metabolism of nifedipine but might decrease the absorption rate. Silymarin was not a potent CYP3A4 inhibitor in vivo [14] . Van Erp and colleagues investigated the effect of milk thistle on the pharmacokinetics of irinotecan, a substrate for CY-P3A4. Neither short-term intake (4 days) nor long-term intake (12 days) of milk thistle showed significant effects on irinotecan clearance [114] . Gurley [86] . In a similar study, 18 healthy volunteers were administered with a standardized milk thistle extract to assess the effect on cytochrome P450 2D6. The study conducted with debrisoquine as a substrate of CYP2D6 also did not suggest the presence of an herb-drug interaction [36] . In a cocktail interaction study with 12 healthy volunteers, he and his colleagues determined long-term supplementation of milk thistle extracts on CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity. They found no statistically significant differences in mean CYP1A2, CYP2D6, CYP2E1, or CY-P3A4 phenotypic ratios [35] .
In summary, current data suggest that milk thistle has no major effects on the activity of CYP enzymes when applied in patients.
Green tea [Camellia sinensis (L.) Kuntze (Theaceae)]
After withering the freshly picked leaves, a brief heating, roasting, or steaming prevents the fermentation of the tea leaves. For this reason, almost all active ingredients such as catechins (70 %), minor flavonols (10%), and polymeric flavonoids (20%) contained in the fresh leaves will remain [19] . The main catechin component of green tea is epigallocatechin gallate (EGCG) that accounts for 50-80% of the catechins in green tea [115, 116] . [117] . Green tea, GTE, and its major active compound ECGC demonstrated antioxidant, anticarcinogenic, anti-inflammatory, antiatherogenic, immunomodulatory, and chemopreventive properties [118] [119] [120] [121] . It has antiatherosclerotic effects on dysfunctional vessels in smokers through increasing the level of nitric oxide and reducing oxidative stress [122, 123] . Green tea may have cardiovascular protecting effects through inhibition of angiotensin-converting enzyme activity [124] . Standardized green tea compounds are effective for decreasing blood pressure, low-density lipoprotein cholesterol, and oxidative stress [125] . The large variety of assumed medical uses of green tea imply that the potential for drug interactions could be high. A clinical study with 11 healthy volunteers assessed the influence of decaffeinated GTE (dGTE) on the activity of CYP2D6 and CYP3A4. The probe substrates dextromethorphan (CYP2D6 activity) and al-prazolam (CYP3A4 activity) were administered orally at baseline, and again after treatment with four dGTE capsules (< 1 mg caffeine) per day for 14 days. No significant differences in dextromethorphan and alprazolam pharmacokinetics were observed at baseline and after treatment with dGTE indicating a lack of effect on CYP2D6 and CYP3A4 [126] . In a clinical cocktail interaction study with 42 healthy volunteers, no clinically significant effects on CYP1A2, CYP2C9, CYP2D6, and CYP3A4 activity for GTE were found [127] . The study participants received a cocktail of CYP metabolic probe drugs, including caffeine, losartan, dextromethorphan, and buspirone for assessing the activity of CYP1A2, CYP2C9, CYP2D6, and CYP3A4, respectively. The subjects underwent 4 weeks of green tea catechin intervention at a dose that contains 800 mg EGCG daily. The intervention did not alter the phenotypic indices of CYP1A2, CYP2C9, and CYP2D6, but resulted in a 20% increase (p = 0.01) in the area under the plasma buspirone concentration-time profile, suggesting a small reduction in CYP3A4 activity [127] .
Overall, both authors concluded that repeated green tea catechin administration is unlikely to modify the disposition of medications metabolized by CYPs.
Valerian [Valeriana officinalis (L.) (Valerianaceae)]
Valerian is a popular remedy prepared from its roots, rhizomes (underground stems), and stolons (horizontal stems). The root is chiefly used for medicinal benefits. It can be found in capsule, tea, tablet, or liquid extract forms. The most abundant constituents of valerian are monoterpenes and sesquiterpenes, including the genus-specific valepotriates and valerenic acid [128] . Valerian root also contains appreciable levels of gamma-aminobutyric acid (GABA) [129] and has sedative, anxiolytic, and hypnotic properties [130] . It is often taken to help alleviate insomnia. There are several clinical studies to evaluate the evidence of efficacy of valerian as a treatment for insomnia [131] [132] [133] [134] .
A clinical study with 12 normal volunteers assessed the influence of a valerian supplement on the activity of CYP2D6 and CYP3A4. The probe substrates dextromethorphan (CYP2D6 activity) and alprazolam (CYP3A4 activity) were administered orally at baseline, and again after exposure to two valerian tablets nightly for 14 days. Valerian showed no clinically relevant effects on the disposition of medications primarily dependent on the CYP2D6 or CYP3A4 pathways for metabolism [135] . In a clinical interaction study with 12 healthy volunteers, the study participants received valerian for 28 days. Probe drug cocktails of caffeine for CYP1A2 activity and midazolam for CYP3A4 activity, followed 24 hours later by debrisoquine for CYP2D6 activity and chlorzoxazone for CYP2E1 activity to avoid potential interference, were administered before (baseline) and at the end of supplementation. Valerian had no significant effect on any CYP phenotypes [85] . In summary, valerian appears unlikely to produce CYP-mediated herb-drug interactions.
Kava [Piper methysticum (G.) Forst. (Piperaceae)]
Kava is still a popular herbal beverage. The commercial products, if not withdrawn from the market for hepatotoxicity, are prepared from dried rhizomes of the kava plant, and the more contemporary dosage form is a capsule, which usually contain a standard 30% of kavalactones. The constituents of kava extract are kavalactones, kawain, methysticin, dihydromethysticin, desmethoxyyangonin, and dihydrokawain [19] . Kavalactones, the assumed active principles, are predominantly concentrated in the plantʼs rhizome rather than in its upper stems or leaves [136] . Ka-valactones effects are a slight numbing of the gums and mouth, and vivid dreams. Kava has been reported to improve cognitive performance and promote a cheerful mood [137] . Kava has anxiolytic and sedative properties and is often suggested to alleviate the symptoms of anxiety [138] . There are only a few clinical studies which revealed the clinical influence of potential interactions mediated by cytochrome P450 enzymes. A clinical study performed by Gurley and colleagues assessed the kava supplementation on human CYP3A activity using midazolam as a phenotypic probe. Sixteen healthy volunteers received kava for 14 days. Midazolam disposition was not affected by kava supplementation [139] . The same research group assessed the influence of kava on the activity of CYP2D6 in a clinical study with 18 healthy volunteers. Kava was not a potent modulator of human CYP2D6 in vivo [36] . A cocktail interaction study in 12 healthy subjects for 28 days showed no significant effects on CYP1A2, CYP2D6, and CYP3A4 activity for kava, but significantly reduced phenotypic ratios for CYP2E1 (~40%, p = 0.009) [85] .
In summary, kava may interact with CYP2E1 substrates. Thus, concomitant ingestion of kava and drugs that are CYP2E1 substrates may increase their therapeutic and adverse effects.
Goldenseal [Hydrastis canadensis (L.) (Ranunculaceae)]
Goldenseal is used as a versatile herbal remedy and has many different medicinal properties. Its roots and rhizomes, which internally are bright yellow in color, have been used as a traditional medicine for the treatment of infection, inflammation, and as an immune system booster. It is taken orally to treat upper respiratory infections and gastrointestinal tract disorders [140] . Modern herbalists consider it an alternative anticatarrhal, anti-inflammatory, antiseptic, astringent, bitter tonic, laxative, and muscular stimulant [140] . Commercial preparations of goldenseal may be purchased in tincture form or as a liquid extract [141] . Goldenseal extract contains isoquinoline alkaloids, including berberine, (+)-and (−)-hydrastine, and lesser amounts of hydrastinine [142] . Chemically, these three goldenseal alkaloids possess a methylenedioxyphenyl moiety, which, in studies of cytochrome P450 (P450) -dependent drug metabolism, frequently give rise to inhibition [142] . Gurley et al. determined the effects of goldenseal supplementation only on human CYP3A activity. Sixteen healthy volunteers received goldenseal for 14 days. Statistically significant increases (p < 0.05) in midazolam AUC (0-∞) (62 %), elimination half-life (57%), and C max (41%) were observed after goldenseal extract supplementation. Goldenseal reduced midazolam apparent oral clearance by 36 % (p < 0.001) [139] . The same research group conducted a clinical assessment in 18 healthy volunteers on the effects of goldenseal only on human CYP2D6 activity. Pre-and post-supplementation phenotypic trait measurements were determined for CYP2D6 using 8-hour debrisoquine urinary recovery ratios. Comparisons of pre-and post-supplementation 8hour debrisoquine urinary recovery ratios revealed significant inhibition (~50 %) of CYP2D6 activity for goldenseal [36] . In a cocktail interaction study, 12 healthy volunteers received goldenseal for 28 days. The probe drug cocktail of midazolam (for CY-P3A4/5 activity) and caffeine (CYP1A2 activity), followed 24 hours later by chlorzoxazone (CYP2E1 activity) and debrisoquine (CYP2D6 activity), were administered before (baseline) and at the end of supplementation. Goldenseal produced significant reductions in CYP2D6 (p < 0.0001) and CYP3A4/5 (p < 0.0001) phenotypes [85] .
Overall, goldenseal seems to be a mild to moderate inhibitor of CYP3A4/5 and CYP2D6. Accordingly, patients should refrain from taking goldenseal supplements concomitantly with prescriptive medications, particularly those extensively metabolized by CYP2D6 and CYP3A4/5.
Other herb-drug interactions
In addition to the herbs described above, there are further plants with therapeutic benefits, which have been investigated with regard to effects on the human cytochrome P450 drug metabolizing system. A clinical study in 12 healthy male subjects showed no effect of ginger [Zingiber officinale (R.) (Zingiberaceae)] on the pharmacokinetic parameters of S-or R-warfarin [49] . A cocktail interaction study investigated the effects of multiple doses of three herbal medicines on metabolic activities of CYP1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 [143] . The roots of Angelica tenuissima (L.) [Apiaceae], Angelica dahurica (L.) [Apiaceae], and Scutellaria baicalensis (L.) [Lamiaceae] were administered to 24 healthy male volunteers. Angelicae tenuissimae radix had no influences on CYP activities. Angelicae dahuricae radix significantly decreased CYP1A2 activity to 10 % of baseline activity (95% CI 0.05-0.21). Scutellariae radix showed significant changes in CYP2C9 and CYP2E1 activities. Baseline values for losartan as a CYP2C9 probe were decreased to 71% (0.54-0.94) and the metabolic activity of chlorzoxazone as a CYP2E1 probe showed a 1.42fold (1.03-1.97) increase [143] . Furthermore, in another study with 17 healthy male subjects, baicalin, a flavone glucuronide of baicalein extracted from Scutellariae radix, significantly induced CYP2B6 activity as measured by bupropion hydroxylation (an average 63 % increase in the AUC ratio of hydroxybupropion over bupropion and an 87 % increase in the AUC of hydroxybupropion) [144] . There are also several other single constituents of plants which may have effects on cytochrome P450 enzymes. For example, resveratrol as the main non-flavonoid polyphenol found in red wine and grapes [Vitis vinifera (L.) (Vitaceae)] has a wide range of biological and pharmacological activities including antioxidant, anti-inflammatory, antimutagenic, and anticarcinogenic effects [145] . A cocktail interaction study in 42 healthy volunteers determined the effect of pharmacological doses of resveratrol on CYP1A2, CYP2C9, CYP2D6, and CYP3A4. Resveratrol intervention was found to inhibit the phenotypic indices of CY-P3A4, 2D6, and 2C9, and to induce the phenotypic index of 1A2 [146] . Curcumin, a yellow curry spice extracted from the rhizome of Curcuma longa (L.) [Zingiberaceae], is a polyphenolic non-flavonoidic that displays anti-inflammatory and antioxidant activities [145] . 
Limitations
Reported drug-herb interaction studies used a broad range of specific preparations of the respective herbs. The information on these preparations is sparse in many of the studies, and even if commercial products have been used, other batches will have different compositions and thus may have different potentials do cause drug-drug interactions. Phytopharmaceuticals composed of different fractions from parts of a plant (leaves, roots, seeds, fruit, other parts) may have completely different compositions. Thus, any extrapolation of the data gathered here to other prod-ucts is flawed to an unknown extent. Furthermore, many studies used invalid phenotyping metrics and/or had small numbers of participants without proper estimation of the sample size required to answer the scientific question. The published literature thus provides only a rough estimate to which extent marketed drugs prepared from specific plants or other preparations of these plants, such as infusions, would indeed cause clinically relevant drug interactions in patients.
Conclusions
!
Our article provides a brief description of clinical interaction studies between phytopharmaceuticals and human cytochrome P450 enzymes for the top 14 common botanicals sales in the U. S. The majority of the herbal drugs appeared to have no clear effects on most of the CYPs examined. If there were an effect, the herbal drugs would qualify as mild inhibitors (less than a 2fold change in enzyme activity) in almost all cases, e.g., in the case of inhibition of CYP2E1 by garlic and by kava or for inhibitory effects of soybean components on CYP1A2. The most pronounced effects were the well-known induction of several members of the CYP family by St. Johnʼs wort and the inhibitory effect of goldenseal on CYP3A and CYP2D6, both being borderline between mild and moderate (more than 2-fold but less than 5-fold) in magnitude. With these two exceptions, concomitant intake of herbal drugs is not a major risk for drugs that are metabolized by CYPs.
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